ARTA
ALXN

A.R.T. Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

A.R.T. Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,519
Closed -$394K – 113
2020
Q4 		$394K Sell
2,519
-3,900
-61% -$501K 1.82% 18
2020
Q3 		$735K Buy
+6,419
New +$692K 4.15% 4
2020
Q1 		– Sell
-14,119
Closed -$1.53M – 1213
2019
Q4 		$1.53M Sell
14,119
-41,281
-75% -$4.42M 0.08% 398
2019
Q3 		$5.43M Buy
+55,400
New +$6.24M 0.27% 64
2019
Q1 		– Sell
-23,800
Closed -$2.32M – 1745
2018
Q4 		$2.32M Buy
23,800
+4,700
+25% +$556K 0.15% 197
2018
Q3 		$2.65M Buy
+19,100
New +$2.4M 0.12% 229
2018
Q2 		– Sell
-59,800
Closed -$6.67M – 1897
2018
Q1 		$6.67M Sell
59,800
-16,000
-21% -$1.91M 0.27% 53
2017
Q4 		$9.06M Sell
75,800
-18,300
-19% -$2.23M 0.4% 22
2017
Q3 		$13.2M Buy
94,100
+39,200
+71% +$5.33M 0.67% 6
2017
Q2 		$6.68M Sell
54,900
-31,000
-36% -$3.61M 0.35% 43
2017
Q1 		$10.4M Buy
+85,900
New +$11.1M 0.48% 24
2016
Q4 		– Sell
-10,500
Closed -$1.29M – 1445
2016
Q3 		$1.29M Buy
10,500
+104
+1% +$13.4K 0.42% 46
2016
Q2 		$1.21M Buy
+10,396
New +$1.48M 0.06% 474
2015
Q2 		– Sell
-114,474
Closed -$19.8M – 1799
2015
Q1 		$19.8M Buy
114,474
+44,552
+64% +$8.06M 0.68% 14
2014
Q4 		$12.9M Buy
+69,922
New +$13M 0.48% 22
2014
Q3 		– Sell
-28,457
Closed -$4.45M – 1604
2014
Q2 		$4.45M Sell
28,457
-13,687
-32% -$2.16M 0.23% 100
2014
Q1 		$6.41M Buy
+42,144
New +$6.7M 0.34% 54
2013
Q4 		– Sell
-41,719
Closed -$4.85M – 1608
2013
Q3 		$4.85M Sell
41,719
-71,169
-63% -$7.81M 0.26% 82
2013
Q2 		$10.4M Buy
+112,888
New +$10.9M 0.34% 49

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

A.R.T. Advisors's ALXN Position: Q1 2021 in Review

A.R.T. Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 2,519 shares — an estimated $394K sold.

A.R.T. Advisors first reported a position in ALXN in Q2 2013 and held it in 19 quarters. The position peaked at $19.8M in Q1 2015. 752 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • A.R.T. Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • A.R.T. Advisors sold 2,519 Alexion Pharmaceuticals shares in Q1 2021, an estimated $394K.
  • A.R.T. Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 19 quarters.
  • A.R.T. Advisors's Alexion Pharmaceuticals position peaked at $19.8M in Q1 2015.
  • 752 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on A.R.T. Advisors's 13F filing for Q1 2021, filed 17 May 2021.